Biogen — Third Quarter 2026 Earnings Summary

Biogen reported third-quarter 2026 total revenue of $2.8 billion, an 11% increase year-over-year, driven by a 49% rise in Growth Portfolio revenue to $1.26 billion. The company posted a GAAP diluted loss per share of $0.14 due to $284 million in acquired in-process research and development expenses, while non-GAAP diluted earnings per share reached $2.62. Biogen raised its full-year 2026 non-GAAP diluted earnings per share guidance range to $12.20–$13.00, reflecting strong business performance and favorable integration of acquired Apellis products.